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Abstract
The breast cancer suppressor BRCA2 is essential for the maintenance of genomic integrity in mammalian cells through its
role in DNA repair by homologous recombination (HR). Human BRCA2 is 3,418 amino acids and is comprised of multiple
domains that interact with the RAD51 recombinase and other proteins as well as with DNA. To gain insight into the cellular
function of BRCA2 in HR, we created fusions consisting of various BRCA2 domains and also introduced mutations into these
domains to disrupt specific protein and DNA interactions. We find that a BRCA2 fusion peptide deleted for the DNA binding
domain and active in HR is completely dependent on interaction with the PALB2 tumor suppressor for activity. Conversely, a
BRCA2 fusion peptide deleted for the PALB2 binding domain is dependent on an intact DNA binding domain, providing a
role for this conserved domain in vivo; mutagenesis suggests that both single-stranded and double-stranded DNA binding
activities in the DNA binding domain are required for its activity. Given that PALB2 itself binds DNA, these results suggest
alternative mechanisms to deliver RAD51 to DNA. In addition, the BRCA2 C terminus contains both RAD51-dependent
and -independent activities which are essential to HR in some contexts. Finally, binding the small peptide DSS1 is essential
for activity when its binding domain is present, but not when it is absent. Our results reveal functional redundancy within
the BRCA2 protein and emphasize the plasticity of this large protein built for optimal HR function in mammalian cells. The
occurrence of disease-causing mutations throughout BRCA2 suggests sub-optimal HR from a variety of domain
modulations.
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Introduction
Precise repair of DNA double-strand breaks (DSBs) in cells is
dependent on homologous recombination (HR), a mechanism that
allows the use of an intact, identical DNA molecule (usually the
sister chromatid) to restore the correct sequence at the site of the
DSB [1,2]. Central to HR reactions is DNA strand exchange
catalyzed by the RAD51 protein. RAD51 forms a nucleoprotein
filament with single-strand DNA (ssDNA) generated by DNA end
resection [3], which then invades a homologous duplex DNA to
initiate HR.
In the cellular context, RAD51 requires several cofactors for its
activity [1]. Proteins termed mediators are critical for RAD51 to
overcome the inhibition to filament formation posed by the high
affinity ssDNA binding protein RPA which otherwise obstructs
RAD51 access to DNA. In mammalian cells, the breast and
ovarian tumor suppressor BRCA2 is postulated to be a key
mediator protein. BRCA2-deficient rodent and human cells are
deficient in HR [4] and have defects in forming DNA damage-
induced RAD51 nuclear foci [5]. Recent studies have illuminated
the biochemical properties of BRCA2 [6–8]. BRCA2 promotes
RAD51 filament assembly specifically onto ssDNA, rather than
dsDNA, allowing it to displace RPA. Further, BRCA2 stabilizes
RAD51 filaments by preventing ATP hydrolysis.
Human BRCA2 is 3418 amino acids and consists of multiple
domains whose relative contributions to HR are somewhat
ambiguous [2] (Figure 1A). The central portion of the protein
contains eight diverged repeats of ,35 amino acids, termed
‘‘BRC’’, which bind RAD51 monomers [9]. When expressed in
cells either individually or as sets of repeats, the BRC repeats
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RAD51 self association [13]. In the context of the full-length
protein, however, the BRC repeats promote RAD51 filament
assembly on ssDNA [6–8]. An additional RAD51 interacting site is
found within the ,200 amino acid C terminus (Cter) of BRCA2
encoded by exon 27 [14]. Unlike the BRC repeats, the Cter does
not bind RAD51 monomers; instead, it interacts with two adjacent
RAD51 protomers in filaments on ssDNA to stabilize them
[15,16]. Isolated from the intact protein, a Cter peptide interferes
with HR in vivo [17], although in the context of otherwise intact
BRCA2, the Cter region promotes HR [4]. RAD51 binding to a
site within the Cter is regulated by CDK phosphorylation of
residue S3291 at G2/M phase [17], which destabilizes RAD51
filaments, and is crucial to at least two processes that are
independent of HR-mediated repair, i.e., maintaining the integrity
of nascent strands at stalled replication forks [18] and preventing
premature entry into mitosis [19].
A large segment of BRCA2 encompasses a DNA binding
domain (DBD) [20]. The DBD contains oligonucleotide/saccha-
ride (OB) folds found in ssDNA binding proteins like RPA, as well
as a long helical domain with a putative dsDNA binding domain at
its apex. Facing away from DNA, the 70 amino acid protein DSS1
also binds to the BRCA2 DBD. DSS1 promotes RAD51 focus
formation upon DNA damage in mammalian cells [21] and also
promotes HR in organisms that do not have a BRCA2 ortholog
[22]. At its N terminus, BRCA2 binds the PALB2 protein, which
also promotes HR [23]. PALB2, like BRCA2, is a breast cancer
suppressor and is also associated with Fanconi anemia, a
developmental and tumor predisposition syndrome [2,24–26].
Because significant portions of the identified activities of
BRCA2 are dedicated to binding RAD51 and ssDNA, we
previously constructed fusion proteins in which one or more
BRC repeats were fused directly to a subunit of RPA [12]. Such
fusion peptides, consisting of as little as 2% of BRCA2, are
functional in promoting HR, implying a primary function for
BRCA2 is to deliver RAD51 to ssDNA.
Given the complex domain structure of BRCA2 and the diverse
domain compositions of BRCA2 orthologs in other organisms
[27], we sought to comprehensively investigate the role of BRCA2
domains in HR. We find that mutations that disrupt DNA binding
in the DBD significantly reduce or abolish HR when PALB2
binding is absent, while deletion of the entire DBD has little
impact on HR when PALB2 binding is present. Moreover,
mutation of a DSS1-binding residue in the DBD abolishes HR
when the DBD is present, even though deletion of the DBD is well
tolerated. We found that the BRCA2 Cter contributes to HR
through both RAD51-dependent and independent activities,
suggesting additional functions for this domain to those identified
thus far. Lastly, a ‘‘micro-BRCA2’’ peptide ,20% the size of full-
length BRCA2 is functional in HR. Thus, our results highlight a
previously unappreciated plasticity within the BRCA2 protein to
promote optimal HR repair in cells.
Results
Mini-BRCA2 peptides proficient in HR in vivo
To determine whether subdomains ofBRCA2could be identified
which are active in HR in vivo, we first generated a series of peptides
consisting of BRC repeats (BRC3, BRC1–2, and BRC1–4) fused
with the BRCA2 DBD [20] (Figure 1B). This same set of BRC
repeatswaspreviouslyfused toRPA70togenerate peptidesactivein
HR [12]. Because the Cter domain located downstream of the
BRCA2 DBD has proved to be important for HR [4], we created a
parallel set of fusion proteins containing the Cter. Collectively, we
termed these peptide fusions ‘‘mini-BRCA2s.’’
HR activity of the mini-BRCA2s was tested in a Brca2 mutant
V-C8 hamster cell line [28] containing an integrated copy of the
DR-GFP reporter [12]. This reporter measures HR repair of an I-
SceI endonuclease-generated DSB in the chromosome by the
restoration of an intact green fluorescent protein (GFP) gene [29]
(Figure 1C). V-C8 cells have a ,20-fold reduction in HR
compared with either wild-type cells [12] or V-C8 cells
complemented with full-length BRCA2 (Figure 1D). Mini-
BRCA2s were transiently expressed together with I-SceI endonu-
clease in V-C8 cells and found to be active in supporting HR
(Figure 1E). However, activity in the Brca2 mutant cells requires
the presence of the Cter. For example, BRC1–4-DBD-Cter
increases HR ,5-fold over background levels, whereas BRC1–4-
DBD is completely inactive. Similar results were obtained for
BRC1–2-DBD-Cter and BRC1–2-DBD, respectively. Although
the peptides can be expressed at somewhat different levels,
expression level does not noticeably affect HR activity (Figure 1F).
These results indicate that the BRCA2 DBD is not equivalent to
RPA in promoting HR. Further, these results demonstrate the
importance of the Cter in HR in vivo, contrasting with results
obtained in vitro where the Cter is not required for recombination
activity [30].
In addition to the Cter, we find that mini-BRCA2s differ from
BRC-RPAs in another important aspect: Mini-BRCA2s are less
active in HR if they contain only a single BRC repeat. Thus,
BRC3-DBD-Cter is marginally active, increasing HR levels only
1.5-fold above background (Figure 1E), while BRC3-RPA activity
is substantial [12]. The small increase in HR nevertheless depends
on the ability of the BRC repeat to bind RAD51, as BRC3D-
DBD-Cter, which contains a deletion of conserved BRC residues
[9,11], is completely inactive (Figure 1E). As the eight BRC
repeats share only limited conservation and bind RAD51 with
different affinities [31] and properties [32], we further tested other
single BRC repeat mini-BRCA2s. We found that both BRC2-
DBD-Cter and BRC4-DBD-Cter are more active than BRC1-
DBD-Cter and BRC3-DBD-Cter, but that neither is as active as
the multiple BRC repeat mini-BRCA2s (Figure 1G). These results
indicate that higher affinity or valency of RAD51 binding is more
critical for mini-BRCA2 function than for BRC-RPA function,
further distinguishing mini-BRCA2 and BRC-RPA function.
Author Summary
The breast tumor suppressor BRCA2 has a major role in
DNA repair by homologous recombination (HR). BRCA2 is a
large protein with multiple domains that interact with
several proteins as well as with DNA, complicating our
understanding of how the protein functions in cells. To
investigate the mechanism by which BRCA2 functions in
HR in cells, we created fusions consisting of various BRCA2
domains and also introduced mutations into these
domains to disrupt specific protein and DNA interactions.
We find that DNA binding by BRCA2 is critical when a
BRCA2 peptide is deficient in binding another breast
cancer suppressor, PALB2, but not when the peptide can
bind PALB2, suggesting alternative mechanisms of activity.
Binding the small peptide DSS1 is also essential for HR only
in some contexts, as are activities in the BRCA2 C terminus.
Our results reveal redundancy of BRCA2 domains and
emphasize plasticity within this large protein built for
optimal HR function in mammalian cells. The occurrence of
disease-causing mutations throughout BRCA2 suggests
sub-optimal HR from a variety of domain modulations.
Plasticity of BRCA2 Function in Recombination
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Mini-BRCA2s active in HR are significantly smaller than full
length BRCA2 – about one third the size – yet they are still
comprised of a number of domains with multiple biochemical
activities and interacting partners. To determine whether mini-
BRCA2s could be further simplified, individual domain require-
ments were tested. Because BRC1–2-DBD-Cter is nearly as
efficient as BRC1–4-DBD-Cter in HR but is more easily detected
on Western blots, it was used to assess the importance of these
other domains. For simplicity, we refer to BRC1–2-DBD-Cter
below as ‘‘mini-BRCA2’’.
The BRCA2 DBD is suggested to be critical for function in HR
through its ssDNA binding activity [20]. The DBD contains three
OB folds [20], which are frequent in ssDNA binding proteins [33].
A co-crystal of the BRCA2 DBD with oligo(dT) demonstrates
binding primarily to OB2, including through interactions similar
to RPA bound to ssDNA [20]. For example, a tryptophan
(W2990) in BRCA2 OB2 is sandwiched between two bases
(Figure 2Ai), similar to a phenylalanine at the same position in
RPA, and a lysine (K2971) interacts with adjacent bases in the
structure through hydrogen bonding (Figure 2Aii). We mutated
these residues in mini-BRCA2 and tested the mutants for HR
proficiency in the V-C8 cells. Mutation of either residue, especially
W2990, significantly reduces HR compared with wild-type mini-
BRCA2 (Figure 2B), indicating that ssDNA binding is critical for
mini-BRCA2 function. HR is not completely abolished with either
Figure 1. HR proficiency of mini-BRCA2 peptides. A. Human BRCA2 domain structure. BRCA2 binds RAD51 at the eight BRC repeats in the
central region of the protein and at a distinct site in the C-terminus (Cter). In addition, BRCA2 binds PALB2 at the N terminus and has a conserved
DSS1 and DNA-binding domain (DBD). B. Mini-BRCA2 domain structures. Peptides contain the indicated BRCA2 domains as well as a nuclear
localization signal (nls) at the N terminus and a FLAG epitope tag at the C terminus. C. DR-GFP. The DR-GFP reporter consists of two defective GFP
genes [29]. Expression of I-SceI endonuclease results in a double-strand break (DSB) at the I-SceI site in the SceGFP gene which can be repaired using
the homologous sequence in the iGFP gene to generate GFP positive cells which are quantified by flow cytometry. D. BRCA2-complemented V-C8
cells have substantially higher DSB-induced HR than uncomplemented cells. P=0.0002, two-tailed unpaired t test. A bacterial artificial chromosome
(BAC) (clone RP11-777I19; BACPAC Resource Center at the Children’s Hospital Oakland Research Institute in Oakland, California) which contains
human BRCA2 [53] was stably introduced into V-C8 DR-GFP cells [12] using a linked neomycin resistance gene for selection. BRCA2 expression was
verified by Western blot analysis (not shown). E. Mini-BRCA2s containing the Cter partially correct the HR defect of Brca2-deficient V-C8 hamster cells.
Mini-BRCA2s that have activity relative to no mini-BRCA2 are BRC3-DBD-Cter (P,0.05), and BRC1–2-DBD-Cter and BRC1–4-DBD-Cter (P#0.001;
unpaired t test). All peptides (red asterisks) are of the expected sizes. BRC1–4-DBD-Cter corrects the HR defect as well or better than BRC1–2-DBD-Cter
despite being poorly detected. F. Comparison of HR activity at different levels of BRCA2 peptide expression. The BRC1–2-DBD-Cter expression vector
was transfected at the usual amount (50 mg) or at a reduced amount (10 mg). HR levels were similar in both cases (P=0.82). G. Mini-BRCA2s with
multiple BRC repeats are more active in HR than those with single BRC repeats. Relative to BRC1–2-DBD-Cter, P#0.0001 for single repeat mini-
BRCA2s, except for BRC2-DBD-Cter where P=0.003. All mini-BRCA2s have significant activity relative to no mini-BRCA2 (P#0.005), except BRCD3-
DBD-Cter (P=0.248).
doi:10.1371/journal.pgen.1002409.g001
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and ssDNA. These results demonstrate the importance of ssDNA-
contact residues for BRCA2 DBD function.
In addition to OB folds, the BRCA2 DBD has a three-helix
bundle (3HB) located at the apex of an unusual ‘‘tower’’ domain
extending from OB2 (Figure 2C). The 3HB is similar to dsDNA-
binding folds and has been implicated in dsDNA binding in vitro
[20]. It has been proposed that nucleation of RAD51 filaments
occurs through BRCA2 bound to ssDNA:dsDNA junctions, which
would explain a role for dsDNA binding in HR reactions [34]. To
test the requirement for the putative dsDNA binding domain, a
mini-BRCA2 was constructed that is deleted for a portion of the
tower (Tdel; Figure 2C, 2D). The Tdel deletion is based on the
same BRCA2 tower deletion previously used for crystallization
[20]; a flexible peptide linker was added to span the distance found
in the crystal structure between the deleted amino acids to attempt
to maintain the overall structural integrity of the DBD. We found
that Tdel is unable to correct the HR defect of the V-C8 cells
(Figure 2E). To more precisely explore the requirement for the
BRCA2 tower domain in HR, the Adel mutation was created in
which only the 3HB at the apex of the tower was deleted
(Figure 2D). A flexible peptide linker was added when constructing
Adel to span the distance between the deleted amino acids. As with
Tdel, Adel is not able to correct the HR defect of V-C8 cells
(Figure 2E). Although we cannot formally rule out the possibility
that the deletions perturb the integrity of the OB2 domain, these
results support a role for the BRCA2 3HB in HR, possibly through
interaction with dsDNA.
Mini-BRCA2 function in HR requires intact DSS1 and
RAD51 Cter binding sites
The BRCA2 DBD binds several proteins, including the small
peptide DSS1 [35], which is reported to promote RAD51 focus
formation after DNA damage [21]. In the co-crystal structure,
DSS1 interacts with the DBD at several residues, in part through a
series of charge interactions [20]. We chose to disrupt one of the
charge interactions, mutating residue K2630 which interacts with
DSS1 residue D17 (Figure 3A). Mutation of this DSS1-interacting
residue in mini-BRCA2 to a neutral amino acid (K2630A) or to an
amino acid of opposing charge (K2630D) results in markedly
reduced or undetectable co-immunoprecipitation with DSS1,
respectively (Figure 3B). Further, both mutations abolish HR
proficiency in vivo (Figure 3C), providing evidence that interaction
with DSS1 is important for mini-BRCA2 function.
Figure 2. Mini-BRCA2 activity requires an intact DBD. A. BRCA2-ssDNA interface in the DBD. BRCA2 OB2 (red) and OB3 (teal) folds interact with
oligo(dT) (green) [20]. i) A key interaction in OB2 is at a tryptophan residue (gold) (W2990 human/W2909 mouse) which stacks with the first two
oligo(dT) bases, in parallel with the first base and at an angle with the second. ii) A lysine (gold) (K2971 human/K2891 mouse), also in OB2, interacts
with the edges of the second and third bases. For the relevant interacting nucleotides and lysine, the nitrogens and oxygens are blue and red,
respectively. Dotted white lines indicate the interaction. Detail of the mouse BRCA2 DBD
DTower-DSS1-oligo(dT) ternary complex [20] extracted from
the RCSB Protein Data Bank, accession code 1MJE. B. Mutations of ssDNA binding residues in mini-BRCA2 impair HR. The mini-BRCA2 in these assays
is BRC1–2-DBD-Cter. For values relative to wild-type mini-BRCA2, P#0.0001; for values relative to no mini-BRCA2, P#0.002; for W2990A compared
with K2971A, P=0.0061. Western blots of the transiently expressed mini-BRCA2s are shown beneath the graph. C. BRCA2 DBD crystal structure
showing the tower domain arising from OB2, with a three-helix bundle (3HB) at the apex of the tower which is proposed to bind dsDNA [20].
Deletions which remove a large part of the tower (Tdel) or only the 3HB (Adel) are indicated on the structure. The structure of the DBD was solved in
a co-crystal with the 70 amino acid protein DSS1 (orange). DSS1 binds in an extended conformation to the helical domain (HD, magenta) and OB1
(green), at the opposite side of the structure from oligo(dT) (not shown). Mouse BRCA2 DBD-DSS1 structure extracted from the RCSB Protein Data
Bank, accession code 1MIU. D. Domain structures of mini-BRCA2s modified within the tower. For Tdel, the seven amino acid linker provides flexibility
for the first tower helix and the disordered region to fold back and reconnect with OB2. For Adel, the three amino acid linker at the site of the
deletion is predicted to connect the ends of the tower without distorting the structure. Boundaries of BRCA2 amino acids deleted are indicated. E.
Deletion of the tower domain or just the 3HB in mini-BRCA2 abrogates HR. For values relative to wild-type mini-BRCA2, P#0.001; relative to no mini-
BRCA2, neither Tdel nor Adel is statistically significant (P=0.53 and 0.58, respectively).
doi:10.1371/journal.pgen.1002409.g002
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homologous to the BRC repeats and which appears to bind
RAD51 differently, having a preference for RAD51 nucleoprotein
filaments as opposed to RAD51 monomers [15,16]. Moreover,
this site is subject to regulated phosphorylation which blocks
interaction with RAD51 [17]. We created two mutations at the
interaction site which abrogate RAD51 binding, S3291A and the
phosphorylation mimic S3291E [17], and found that both
substantially reduce the HR activity of the mini-BRCA2
(Figure 3D). These results suggest that two modes of RAD51
binding – at the BRC repeats and at the Cter – are important for
mini-BRCA2 activity in HR.
In summary, this series of mutations within the various domains
of mini-BRCA2 provides evidence that binding to ssDNA,
dsDNA, DSS1, and RAD51 (in two modes) are all required for
mini-BRCA2 function in HR in vivo.
PALB2-binding increases the HR proficiency of BRCA2
fusion peptides
Mini-BRCA2s are functional for HR but they only partially
restore HR levels to BRCA2-deficient V-C8 cells. Mini-BRCA2s
are missing the N-terminal ,30% of BRCA2, including the
interaction site for the PALB2 protein found in the first ,50 amino
acids of BRCA2 [23]. Given that mutations that impair PALB2
binding impair the ability of full-length BRCA2 to function in HR
[23], we added the PALB2interaction site to mini-BRCA2, forming
what we termed midi-BRCA2-1 (Figure 4A). We also added a
longer segment so that the N-terminal region of BRCA2 was largely
restored (midi-BRCA2-2). Midi-BRCA2s are expressed at the
expected sizes, although the level of midi-BRCA2-2 detected on
Western blots is low compared with either midi-BRCA2-1 or mini-
BRCA2 (Figure 4B). Both midi-BRCA2-1 and midi-BRCA2-2
complement the HR defect of V-C8 cells to a greater extent than
mini-BRCA2,leadingto a 3 to4-foldhigherlevelof HR(Figure 4C)
and approaching that of full-length BRCA2 (Figure 1D).
To determine if the higher level of HR is due to interaction with
PALB2, we disrupted the PALB2 binding site of the midi-
BRCA2s. BRCA2 W31 is a key contact residue with PALB2,
projecting into a hydrophobic pocket of the PALB2 ß-propeller
(Figure 4D, [36]). W31C mutation, which is annotated in the
Breast Cancer Information Core (BIC) database, impairs the
interaction of full-length BRCA2 with PALB2 and impairs HR
function [23]. By contrast, mutation of BRCA2 residue I27 does not
impact binding to PALB2 or HR. Similarly, we find that W31C
mutation of either midi-BRCA2-1 or midi-BRCA2-2 reduces
binding to PALB2 whereas I27C mutation does not (Figure 4D;
data not shown), while neither mutation affects the expression of the
midi-BRCA2s (Figure 4E, 4F). Importantly, W31C mutation
markedly reduces the ability of the midi-BRCA2s to function in
HR, whereas I27C mutation does not (Figure 4E, 4F). These results
indicatethatinteraction ofthe midi-BRCA2s with PALB2promotes
HR. HR is not completely abolished by W31C mutation, however,
as HR activity for either of the midi-BRCA2 mutants is similar to
that of mini-BRCA2 (Figure 4E, 4F). Combined mutation of the
Cter RAD51 binding site (S3291A) and W31C, however, severely
compromises midi-BRCA2-2 function inHR (Figure 4F), indicating
that when the PALB2 binding site is disrupted, the residual activity
in the midi-BRCA2-2 requires the Cter RAD51 binding site for
activity, as does mini-BRCA2 (Figure 2I).
Interaction with PALB2 partially compensates for
mutations in domains essential for mini-BRCA2 HR
activity
Given that the PALB2 binding site has a strong effect on HR
activity, we asked how this effect is modulated by activities from
the DBD. In the context of PALB2 binding, substitution mutations
in ssDNA binding residues in DBD OB2 in midi-BRCA2s
decrease HR ,50% (Figure 5A), whereas these same mutations
in mini-BRCA2 reduce HR close to background levels (note
especially W2990A; Figure 2B). Likewise, the Tdel and Adel
mutations in the DBD tower domain modulating dsDNA
interaction only mildly affect HR activity of midi-BRCA2s
(,50% HR reduction, Figure 5B) but completely abolish HR
activity of mini-BRCA2 (Figure 2E). These results indicate that the
ability of the midi-BRCA2s to interact with PALB2 partially
compensates for disruption of ssDNA and dsDNA binding, both of
which otherwise become essential for HR activity.
We also investigated the importance of DSS1 binding for midi-
BRCA2 function. Although the interaction between BRCA2 and
DSS1 occurs within the DBD, it likely does not affect DNA
binding as it occurs at a distance from the DNA binding residues
(Figure 2C). The DSS1-binding mutation K2630D completely
Figure 3. Mutation of a DSS1-interacting residue or the Cter RAD51-interacting residue S3291 significantly reduces the HR activity
of mini-BRCA2. A. Detail of the BRCA2-DSS1 interface. BRCA2 and DSS1 interact through both charged and hydrophobic residues [20]. For the
former, basic residues in BRCA2 interact with acidic residues in DSS1 (e.g., K2630 human/K2551 mouse interacts with DSS1 D17; white). Detail of the
mouse BRCA2 DBD-DSS1 structure [20] extracted from the RCSB Protein Data Bank, accession code 1MIU. B. Mutation of BRCA2 K2630 in mini-BRCA2
reduces DSS1 interaction. Immunoprecipitation of myc-tagged DSS1 brings down FLAG-tagged wild-type mini-BRCA2 but K2630A or K2630D-
mutated mini-BRCA2 to a much lower or undetectable level, respectively. C. Mutation of a DSS1 interacting residue in mini-BRCA2 abrogates HR. For
values relative to wild-type mini-BRCA2, P#0.001; relative to no mini-BRCA2, neither K2630A nor K2630D is statistically significant. D. Mutation of the
Cter RAD51 binding site in mini-BRCA2 impairs HR. For values relative to wild-type mini-BRCA2, P#0.0001; relative to no mini-BRCA2, P#0.0001.
doi:10.1371/journal.pgen.1002409.g003
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DSS1 binding as an important activity of the BRCA2 peptides
whether or not the peptides can bind PALB2. The K2630A
mutation (Figure 2G), which does not completely abolish DSS1
binding, also substantially reduces HR activity of midi-BRCA2-2
(Figure 6A). Thus, loss of DSS1 binding and loss of DNA binding
are not equivalent.
Finally, we investigated the role of the Cter RAD51-binding site
in midi-BRCA2 function. Mutations at S3291 in midi-BRCA2
only partially reduce HR (#50%, Figure 6B), similar to the two
DNA binding mutations, and in contrast to the DSS1-binding
mutation. Thus, the midi-BRCA2s are not strictly dependent on
three of the four activities we identified to be important for mini-
BRCA2 function, indicating that the ability to bind PALB2 can
override the requirement for other activities. However, the
requirement for DSS1 binding is maintained in the midi-BRCA2s.
HR in the absence of the BRCA2 DBD
The substantial HR activity remaining for midi-BRCA2s
mutated in the DBD or Cter domain led us to ask whether
proteins deleted for these domains could be functional in HR.
Gene disruption alleles with the potential to express peptides
truncated after BRC3 or BRC7 permit survival of mice [37,38],
whereas those truncated before the BRC repeats do not [39],
suggesting that N-terminal BRCA2 peptides retaining BRC
repeats retain partial function. Further, a PARP-inhibitor
insensitive BRCA2 revertant deleted for BRC6 through the
DBD (PIR2) has been identified which is active in HR [40].
To address this, we created a series of truncated and internally
deleted BRCA2 peptides (Figure 7A). Peptides truncated after
BRC3 and BRC5 (i.e., TrBRC3 and TrBRC5, respectively) do
not increase HR activity (Figure 7B), indicating that the PALB2
interacting site and BRC repeats are not sufficient to restore HR
activity to V-C8 cells. By contrast, the addition of the Cter,
creating TrBRC3-Cter, leads to substantial HR activity, demon-
strating the importance of the Cter domain for HR activity of the
truncations. Similarly, TrBRC5-Cter, corresponding to the
previously described PIR2 revertant [40], is also active in HR.
These results demonstrate that the DBD is not essential for HR
and that as few as three BRC repeats can suffice for HR activity in
Figure 4. Midi-BRCA2s containing an intact PALB2 binding site restore HR levels. A. Midi-BRCA2 domain structures. Midi-BRCA2s contain
the PALB2-interacting domain at the N terminus. Midi-BRCA2-2 differs from full-length BRCA2 primarily in being deleted for the last 6 BRC repeats; it
also contains a small deletion N-terminal to BRC1. B. Western blot analysis showing expression of the transiently expressed mini and midi-BRCA2s. C.
Midi-BRCA2s are more proficient at HR than mini-BRCA2. Relative to mini-BRCA2, P#0.0001 for midi-BRCA2s. D. BRCA2 W31 is a key PALB2 binding
residue. Mutation of midi-BRCA2 W31 disrupts binding to PALB2. Immunoprecipitation of FLAG-tagged wild-type or I27C midi-BRCA2 efficiently
brings down PALB2 while FLAG-tagged W31C midi-BRCA2 precipitation of PALB2 is significantly impaired. BRCA2 W31 extends from a short helix into
a hydrophobic pocket of the PALB2 ß-propeller; the indole nitrogen (light blue) also supports a polar interaction with a water bridge to PALB2 S1065
in the PALB2 pocket (dotted line) [36] (accession code 3EU7). Only a portion of the PALB2 ß-propeller is shown. E. Mutation of the PALB2 binding site
(W31C) in midi-BRCA2-1 reduces but does not abolish HR activity. For values relative to wild-type midi-BRCA2-1, P#0.0001 except for midi-BRCA2
I27C, which is not significant; for mini-BRCA2 relative to midi-BRCA2-1 W31C, P=0.13. Western blot analysis shows expression of the transiently
expressed mini and midi-BRCA2s. F. Mutation of the PALB2 binding site (W31C) in midi-BRCA2-2 reduces but does not abolish HR activity. Relative to
wild-type midi-BRCA2-2, P#0.005 for the W31C and/or S2391A mutants; for midi-BRCA2-2 W31C relative to no midi-BRCA2-2, P#0.0001 whereas
W31C+S3291A is not significantly different from no midi-BRCA2-2 (P=0.13). Western blot analysis shows expression of the transiently expressed
peptides.
doi:10.1371/journal.pgen.1002409.g004
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intermediate activity between that of mini-BRCA2 and midi-
BRCA2-2, but similar activity to the apex deletion in midi-
BRCA2-2, consistent with the DBD contributing to, but not being
required for, HR.
The importance of the Cter for the function of the BRCA2
truncations led us to test the effect of mutations at the RAD51
interaction site. Both S3291A and S3291E reduce HR activity for
the TrBRC-Cter peptides, but do not eliminate it (Figure 7B).
These results suggest that the Cter has additional functions to
RAD51 binding which enhance the activity of the truncations.
Given the absence of a DBD in the BRCA2 truncations, we
speculated that PALB2 binding would be essential for their activity.
To test this, we introduced the W31C mutation into TrBRC5-Cter,
which substantially reduces its binding to PALB2 (Figure 7C). This
mutant protein demonstrates no HR activity (Figure 7C), indicating
that in the absence of DNA binding, HR activity is entirely
dependent on the ability of this peptide to interact with PALB2.
Figure 5. Interaction with PALB2 partially compensates for mutations in the DNA binding domain. A. Midi-BRCA2s with mutations in
ssDNA contact residues retain substantial HR activity. P#0.0001 compared with no BRCA2 peptide. i) Compared with wild-type midi-BRCA2-1, P
values are 0.002 (W2990A), 0.05 (K2971A), and 0.01 (K2971E). ii) Compared with wild-type midi-BRCA2-2, P values are 0.0004 (W2990A), 0.15 (K2971A),
and 0.0002 (K2971E). Western blot analysis shows expression of the transiently expressed peptides. B. Midi-BRCA2s with deletion of the tower domain
or just the three-helix bundle retain partial HR activity. P#0.0002 compared with no BRCA2 peptide. Compared with the respective wild-type
proteins, P values for mini-BRCA2 mutations are 0.003 (Tdel) and 0.0008 (Adel) (Figure 2E), for midi-BRCA2-1 are 0.002 (Tdel) and 0.02 (Adel), and for
midi-BRCA2-2 are 0.0001 (Tdel, Adel). Western blot analysis shows expression of the transiently expressed peptides.
doi:10.1371/journal.pgen.1002409.g005
Figure 6. Interaction with PALB2 partially compensates for point mutations in the Cter that interfere with RAD51 binding, but
cannot compensate for mutations that interfere with DSS1 binding. A. Mutation of a DSS1 interacting residue in midi-BRCA2 abrogates HR.
For midi-BRCA2-2, K2630A and K2630D mutations in comparison with no BRCA2 peptide are not significantly different (P=0.08 and 0.52,
respectively), while compared with the respective wild-type proteins, they are (mini-BRCA2, P#0.001, as in Figure 2H; midi-BRCA2-2, P,0.0001). B.
Midi-BRCA2s with mutation of the Cter RAD51 binding site retain partial HR activity. P#0.0001 compared with no BRCA2 peptide or with the
respective wild-type proteins. Western blot analysis shows expression of the transiently expressed peptides.
doi:10.1371/journal.pgen.1002409.g006
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Our results with the truncated peptides suggest functional
redundancy within BRCA2 and raise the possibility that BRCA2
could be pared down further yet retain HR activity. To test this,
we fused the PALB2-interaction domain to two BRC repeats and
the Cter, creating a micro-BRCA2 which is ,20% the size of full-
length BRCA2 (Figure 8A). The micro-BRCA2 is expressed
(Figure 8B) and is active in HR (Figure 8C); indeed, correction of
HR by the micro-BRCA2 was higher than by the mini-BRCA2
(Figure 8C). Given that the PALB2 interaction domain and the
Cter are required for activity of the truncations (Figure 7B, 7C), we
asked whether these two domains are sufficient to promote HR by
creating another derivative peptide without BRC repeats, zippo-
BRCA2 (Figure 8A). Zippo-BRCA2 is expressed (Figure 8B) but is
completely inactive (Figure 8C). Thus, as with mini-BRCA2, the
Cter RAD51 interaction site is not sufficient to promote HR, such
that micro-BRCA2 likely has a minimal domain set required for
an active BRCA2 peptide.
Discussion
Using domain fusions, we investigated here which elements of
BRCA2 are critical for HR in vivo. From our results, we can
conclude that significant portions of BRCA2 are not essential for
HR activity and, further, that functional redundancy exists within
this large protein. Two types of active BRCA2 peptides can be
distinguished in V-C8 cells based on the absence or presence of the
BRCA2 DBD – micro-BRCA2 and mini-BRCA2, respectively
(Figure 8D). In the absence of the DBD, the ability to interact with
PALB2 becomes essential for detectable HR activity. Common to
both forms is the requirement to bind RAD51 through the BRC
repeats as well as the contribution of the Cter, which exhibits
RAD51-dependent as well as independent activities.
DNA binding in the DBD is required only for mini-BRCA2
activity
The correction of the HR defect of BRCA2-deficient cells with
BRC-RPA fusions implied that the major activity of BRCA2 in
HR is to deliver RAD51 to ssDNA [12] (Figure 8E). Biochemical
studies support this interpretation, as full-length BRCA2
promotes RAD51 filament formation specifically on ssDNA [6–
8]. We established that ssDNA binding is indeed required for the
activity of BRCA2 peptides that lack the PALB2 interaction site:
mini-BRCA2s mutated at ssDNA-binding residues in OB2 of the
DBD show little HR activity. By contrast, midi-BRCA2s mutated
for ssDNA binding retain substantial HR activity, as do micro/
Tr-BRCA2s deleted for the DBD. Thus, ssDNA binding in the
DBD becomes essential for activity in the absence of PALB2
binding. Binding to PALB2 may allow BRCA2 to interact
indirectly with DNA, bypassing the need for the DBD itself (see
below).
In addition to ssDNA, BRCA2 has been postulated to bind
dsDNA through the tower domain 3HB, given the structural
similarity of the 3HB to dsDNA binding domains in other
proteins and biochemical studies with a DBD deleted for the
tower [20]. Through deletion analysis, we provide evidence that
the 3HB of the DBD is required for mini-BRCA2 function. Dual
binding to ssDNA and dsDNA is proposed to support the
recruitment of BRCA2 to ssDNA-dsDNA junctions (Figure 8E),
HR intermediates arising from DNA end resection, to nucleate
Figure 7. BRCA2 DBD is not required for HR in peptides that bind PALB2. A. Tr-BRCA2 domain structures. All Tr-BRCA2 peptides are deleted
for C-terminal BRC repeats and the BRCA2 DBD at the indicated residues. TrBRC3 and TrBRC5 are additionally deleted for the Cter. TrBRC5-Cter
corresponds to a BRCA2 peptide expressed in a PARP inhibitor-resistant revertant of Capan-1 cells (PIR2; [40]). B. TrBRC-Cter peptides are functional
for HR whereas TrBRC peptides are not. The RAD51 binding site at S3291 contributes to HR activity but is not the sole determinant. P#0.0001 for
TrBRC-Cter compared with the respective no Cter or S3291-mutated Cter. C. Disruption of PALB2-binding by W31C mutation (right) is associated with
impaired TrBRC5-Cter HR activity (left). P=#0.0001 for TrBRC5-Cter compared with the W31C mutation.
doi:10.1371/journal.pgen.1002409.g007
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ortholog from Ustilago, Brh2 [34]. Binding to ssDNA-dsDNA
junctions would appear to differentiate BRCA2 from the BRC-
RPA fusion, which does not have a dsDNA binding domain; the
high affinity of RPA to ssDNA may allow the BRC-RPA fusion to
bypass junctional binding. Unlike BRCA2 and Brh2, the BRCA2
ortholog from C. elegans, BRC-2, does not have a tower domain,
and the single OB fold in BRC-2 is more related to OB folds in
RPA than in BRCA2 [41]. Thus, it seems possible that BRC-2
may act more akin to BRC-RPA fusions, delivering RAD51
directly to ssDNA.
DSS1 binding is required in BRCA2 peptides containing a
DBD
DSS1 is known to promote HR [21,42], even in budding yeast
which does not have a BRCA2 homolog [22], raising the question
as to whether the interaction with DSS1 is important for BRCA2
function. We found that interaction with DSS1 is required for HR
activity of both mini and midi-BRCA2s, but not for micro/Tr-
BRCA2s in which the DBD – and hence DSS1 contact residues –
were deleted. Notably, the only mutation in midi-BRCA2 found to
render it completely inactive for HR was one that abrogates DSS1
binding (K2630D). Thus, if the DBD is present, interaction with
DSS1 is critical for BRCA2 function; however, if the DBD is
absent, DSS1 binding is not required for activity, similar to what
has been observed with Ustilago Brh2 [43].
PALB2 interaction overrides the requirement for the DBD
An intact PALB2 interaction site in midi-BRCA2s results in
substantially higher HR activity than that found with mini-
BRCA2s, and partially overrides mutations that inactivate the
mini-BRCA2s (i.e., in OB2, the 3HB, or the Cter). PALB2 was
initially identified as an interacting protein with BRCA2 [23], but
it has also been found to interact with other HR proteins,
including BRCA1, with which it may form a bridge to BRCA2
[44,45], and the RAD51 interacting protein, RAD51AP1 [46].
More recently, PALB2 has also been shown to bind DNA and
RAD51 and stimulate D-loop formation in vitro; although this
activity can function independently of BRCA2 [46], it can also
synergize with a BRCA2 peptide fusion that is similar to our midi-
BRCA2s [47].
That the interaction with PALB2 has such a great impact on
HR suggests that BRCA2 typically functions in a complex with
PALB2 and provides insight into how BRCA2 peptides lacking
most of the protein, in particular micro-BRCA2, remain
proficient for DSB repair (Figure 8E). Possibly, three different
modes of RAD51 binding within the BRCA2/PALB2 complex
participate in HR, two from BRCA2 and one from PALB2. Our
results also show, however, that the absence of BRC repeats
(zippo-BRCA2) cannot be compensated for by interaction with
PALB2, implying that activities carried by PALB2, notably
binding to RAD51, are not sufficient to restore BRCA2 peptide
function.
Figure 8. BRCA2 peptides functional in HR. A. Micro-BRCA2 domain structure. Micro-BRCA2 contains three domains – the PALB2 interaction site,
BRC1–2, and the Cter, whereas zippo-BRCA2 is deleted for the BRC repeats. B. Western blot analysis showing expression of the indicated BRCA2
peptides. C. Comparison of HR activity of various BRCA2 peptides. Micro-BRCA2 is more active than mini-BRCA2 (P=0.0024), whereas zippo-BRCA2 is
not active. D. Summary of BRCA2 peptides and their relative HR activity. E. Schematic of peptides active in HR. While full-length BRCA2 has optimal HR
activity, BRCA2 peptides can be derived which have substantial activity. Those that bind PALB2, such as micro-BRCA2, are active even with a deleted
DNA binding domain (DBD). In the absence of PALB2 binding, an intact DBD is critical for HR activity. BRC fusion to RPA, however, can bypass the
requirement for the DBD.
doi:10.1371/journal.pgen.1002409.g008
Plasticity of BRCA2 Function in Recombination
PLoS Genetics | www.plosgenetics.org 9 December 2011 | Volume 7 | Issue 12 | e1002409RAD51-dependent and -independent activities within the
BRCA2 Cter
The first link between BRCA2 and RAD51 came about
through the identification of an interaction between the BRCA2
Cter and RAD51 [14], with subsequent studies localizing RAD51
binding to a peptide in the middle of the Cter, specifically
involving residue S3291 [17]. Importantly, this Cter peptide
binds to and stabilizes RAD51 filaments, but does not bind
RAD51 monomers [15–17]. The importance of RAD51 binding
in the Cter is clear, as S3291 mutation either has a severe effect
on HR activity (mini-BRCA2, midi-BRCA-2 W31C) or reduces it
by ,40% (midi-BRCA2s, TrBRC-Cter). We recently found that
the S3291A mutation introduced into full-length BRCA2 by BAC
mutagenesis restores HR in V-C8 cells to the same extent as wild-
type BRCA2 [18], similar to results obtained in human and
chicken cells [19,48]. Thus, Cter S3291A mutation leads to a
gradient of HR defects, from severe to undetectable, depending
on the context.
The inability of zippo-BRCA2, which does not contain BRC
repeats, to restore HR in V-C8 cells implies that the Cter is not
able to deliver RAD51 to DNA. However, once RAD51 filament
assembly is initiated by the BRC repeats, the Cter may stabilize
filaments that otherwise would not mature sufficiently in partially
HR compromised fusion-peptide backgrounds, providing an
explanation for the gradient of HR activity.
Unlike the S3291A point mutation, deletion of the Cter
in otherwise full-length BRCA2 leads to a moderate HR defect
[4]. S3291 mutation and Cter deletion also have differential
effects on HR in BRCA2 peptides (e.g., compare TrBRC with
TrBRC-Cter S3291A; Figure 7B). More severe HR phenotypes
with deletion of the Cter suggest that the Cter has a function in
HR beyond simply binding RAD51. The only other function
attributed thus far to the Cter is to promote nuclear localization
of the protein [49], but given that all peptides contain an nuclear
localization signal at the N terminus, the function of the Cter is
unlikely to simply be to direct the protein to the nucleus. It is
notable that although Ustilago Brh2 contains a DBD related to the
BRCA2 DBD, a second DNA binding domain is present in Brh2
which is the primary determinant for DNA binding for this
protein [50]. However, as yet there is no evidence that BRCA2,
in particular the Cter, harbors an additional DNA binding
domain.
Functional BRCA2 peptides with reduced BRC repeat
number
While BRC repeats promote the nucleation of RAD51 filaments
on ssDNA [51], one and two BRC repeats are sufficient to
promote HR activity of the BRC-RPA and BRCA2 peptide
fusions, respectively, and adding more BRC repeats does not
substantially increase HR activity. Secondary mutations in
BRCA2 that reverse cisplatin and PARP inhibitor sensitivity of
BRCA2 mutant cells have been identified which delete up to six
BRC repeats, yet retain HR proficiency [40,52], consistent with a
lack of requirement for all eight repeats for BRCA2 function.
The BRCA2 peptide analysis presented here suggests a plausible
explanation for why BRCA2 evolved to contain multiple BRC
repeats: The compelling difference between midi-BRCA2-2 and
full-length BRCA2 is the number of BRC repeats (two and eight
BRC repeats, respectively), but only midi-BRCA2-2 shows an HR
defect with Cter mutation. A larger number of BRC repeats in the
full-length protein could increase the frequency of nucleation of
RAD51 nucleoprotein filaments [51], allowing it to circumvent the
requirement for filament stabilization by the Cter.
Plasticity of BRCA2 structure: implications for
tumorigenesis
Taken together, our results point to the plasticity of BRCA2 for
HR function in vivo. While full-length BRCA2 is built to ensure
efficient RAD51 filament formation and stabilization for optimal
HR, multiple domain deletions and point mutations which
compromise interactions only partially reduce HR, such that in
the extreme, a peptide ,20% the size of BRCA2 (micro-BRCA2)
provides substantial HR activity.
This remarkable intragenic redundancy, however, may have a
downside. Reduced HR efficiencies may not elicit cell death, yet
may also not be sufficient to maintain genomic stability, especially
when extensive repair is required. This could have profound
implications for tumorigenesis. Indeed, mutations are found
throughout the BRCA2 gene in breast cancer patients (BIC
database) suggesting an involvement of all functional domains in
maintaining genomic stability. A large number of BRCA2 variants
have been identified in the population, the significance of which to
BRCA2 function and tumorigenesis are unknown. By exploiting
BRCA2’s functional plasticity, our system with partially compro-
mised fusion peptides provides a fast and sensitive means to detect
mutations affecting HR, many of which may be phenotypically
overlooked in assays utilizing full-length BRCA2.
Materials and Methods
HR assays
The BRCA2 mutant V-C8 hamster cell line [28] contains a
single integrated copy of DR-GFP reporter [12]. For HR assays,
5610
6 exponentially growing cells were collected and resuspended
in 650 ml Opti-MEM media (Invitrogen) in a 0.4-cm cuvette
(Biorad) with 50 mg each of the I-SceI expression vector pCBASce
(or the empty pCAGGS vector) and the expression vector for a
BRCA2 peptide (see below). Cells were transfected by electropo-
ration (280 V and 1000 mF) with a Biorad Gene Pulser II. HR was
measured by counting the number of GFP-positive cells using a
Becton Dickinson FACSscan 48 h after electroporation. Most HR
results were derived from 5 to 9 transfections from at least 3
independent experiments, except results in Figure 3C and
Figure 6A which were derived from 3 transfections. P values were
calculated using an unpaired t test through Graphpad software
(http://www.graphpad.com/quickcalcs/ttest1.cfm).
Plasmids
Vectors expressing BRCA2 peptides have a pCAGGS back-
bone. All peptides contain an N-terminal nuclear localization
signal and a C-terminal FLAG epitope tag [12]. Mini-BRCA2
vectors were derived by modifying vectors encoding BRC-RPA
fusions [12], such that individual BRC motifs correspond to amino
acids 996–1064 (BRC1), 1206–1274 (BRC2), 1415–1483 (BRC3),
and 1511–1575 (BRC4) of human BRCA2 and multiple BRC
motifs correspond to amino acids 923–1252 (BRC1–2) and 923–
1563 (BRC1–4) of mouse BRCA2. To generate the mini-BRCA2s,
the vector fragment encoding RPA70 in the BRC-RPA fusion was
swapped with a fragment encoding the BRCA2 DBD (residues
2451–3210) or the DBD through the Cter (residues 2451–3418).
BRCA2 fragments were amplified by PCR using a human BRCA2
full-length cDNA as a template and a C-terminal primer designed
to maintain the FLAG epitope.
Midi-BRCA2 vectors were generated by introducing a fragment
encoding human BRCA2 residues 1 to 200 (midi-BRCA2-1) or 1
to 950 (midi-BRCA2-2) at a site located between the nuclear
localization signal sequence and BRC1–2 in mini-BRCA2.
TrBRC peptides encode human BRCA2 until residue 1510
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additionally encode residues 3226–3418 of human BRCA2.
Adel and Tdel were generated by PCR to delete BRCA2
residues 2889–2959 (Tdel) and 2889–2919 (Adel) and insert short
peptide linkers SGSGSGS (Tdel) and SGS (Adel). Tdel is based on
the BRCA2 peptide, DTower, used for biochemical studies in
which much of the tower was cleaved from the mouse BRCA2
DBD using TEV protease [20]. In DTower, tower alpha helix 1
(Ta1) is maintained but the other tower helices (Ta2–Ta5) are
removed [20]. In Tdel, the approximately 20 amino acids after
Ta1 that are disordered in the structure are maintained and
followed by the 7 amino acid peptide linker, which then connects
with the base of the tower prior to OB2 at the same position of
TEV protease cleavage. In Adel, only the 3HB helices (Ta2–Ta4)
are deleted.
The DSS1 expression vector was generated by inserting the
human DSS1 cDNA into pCAGGS with an N-terminal c-myc tag.
The PALB2 expression vector was generated by inserting human
PALB2 into a modified pEGFP-N3 (Clontech) vector with an
added N-terminal c-myc tag. The resulting construct expresses
PALB2 with a myc tag at the N terminus and a GFP tag fused at
the C terminus.
Protein analysis
BRCA2 peptide expression was examined 48 h after electropo-
ration by Western blotting using 40–100 mg of total lysate
separated by 10% Tris-Glycine or 4–12% Bis-Tris polyacrylamide
gel electrophoresis (Invitrogen). Membranes were probed with
anti-FLAG-M2 antibody (A8592, Sigma) or anti-alpha-tubulin
antibody (T6074, Sigma) to assess protein loading. For co-
immunoprecipitations, V-C8 cells were electroporated as above
with 50 mg each of the expression vectors for the BRCA2 peptide
and PALB2 or DSS1. Cells were collected ,40 h after
electroporation and resuspended in NETN buffer (150 mM NaCl,
1 mM EDTA, 50 mM Tris-HCl, pH 8.0, 0.5% NP40) containing
protease inhibitor (Complete Mini Roche). Cell lysates were
obtained by repeated cycles of freezing (dry ice/ethanol) and
thawing (warm water). For PALB2, protein extracts from cells
expressing midi-BRCA2-1 and TrBRC5-Cter (600 mg) and midi-
BRCA2-2 (450 mg) were incubated with 40 ml EZview Red ANTI-
FLAG M2 Affinity Gel (Sigma F2426) for 5–6 h at 4uC. Proteins
were eluted with SDS-PAGE sample buffer and loaded on a
BIORAD ready gel 7.5% Tris-HCl (100–150 V, ,2 h) and then
transferred to a nitrocellulose membrane overnight at 4uC.
Membranes were blocked using TBS-Tween 20–5% BioRad
Non-Fat Dry Milk and probed with anti-PALB2 antibody M11
raised against amino acids 601 to 880 of human PALB2 and
monoclonal anti-FLAG M2-Peroxidase (HRP) antibodies. For
Western blotting, 50 mg of protein were loaded on a BIORAD
ready gel 7.5% Tris-HCl. For DSS1, co-immunoprecipitations
were performed with 100–500 mg whole cell extract and 20 mlo f
anti–c-myc Agarose Affinity Gel (A7470, Sigma) for 4 h to
overnight at 4uC. Immune complexes were washed with lysis
buffer and separated by 4–12% Bis-Tris polyacrylamide gel
electrophoresis. Membranes were probed with anti-FLAG-M2
antibody.
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